One week after the FDA received its first request to approve a biosimilar medicine, a handful of U.S. senators has asked the U.S. Department of Health and Human services when a formal policy will be adopted for naming these medications.. Their missive was sent just as the World Health Organization suggested a new proposal for naming biosimilars, which are designed to emulate brand-name biologics and are forecast to save billions of dollars in health care costs.